In this issue of Blood, Gagelmann et al1 describe an integrated clinical-molecular prognostic model (Myelofibrosis Transplant Scoring System [MTSS]) to predict outcome post stem cell transplant (SCT) in myelofibrosis (MF). MF is a clonal stem cell neoplasm with heterogeneous clinical phenotypes and well-defined driver mutations found in ∼90% of the cases.2 Despite the introduction of JAK inhibitors,3 MF still remains an incurable disease with a median survival of 4 to 5 years. SCT is an option for MF patients,4 but, because of the very high risk of mortality, the patient selection is very critical.
Stem cell transplant in MF: It’s time to personalize
Passamonti F.
Primo
Writing – Original Draft Preparation
2019-01-01
Abstract
In this issue of Blood, Gagelmann et al1 describe an integrated clinical-molecular prognostic model (Myelofibrosis Transplant Scoring System [MTSS]) to predict outcome post stem cell transplant (SCT) in myelofibrosis (MF). MF is a clonal stem cell neoplasm with heterogeneous clinical phenotypes and well-defined driver mutations found in ∼90% of the cases.2 Despite the introduction of JAK inhibitors,3 MF still remains an incurable disease with a median survival of 4 to 5 years. SCT is an option for MF patients,4 but, because of the very high risk of mortality, the patient selection is very critical.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
